- Home
- IMMP vs SPOK Comparison
IMMP vs SPOK Comparison
Compare IMMP & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- SPOK
- Stock Information
- Founded
- IMMP 1987
- SPOK 2004
- Country
- IMMP Australia
- SPOK United States
- Employees
- IMMP N/A
- SPOK N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- SPOK Telecommunications Equipment
- Sector
- IMMP Health Care
- SPOK Telecommunications
- Exchange
- IMMP Nasdaq
- SPOK Nasdaq
- Market Cap
- IMMP 211.1M
- SPOK 318.9M
- IPO Year
- IMMP N/A
- SPOK 1992
- Fundamental
- Price
- IMMP $1.86
- SPOK $16.54
- Analyst Decision
- IMMP Buy
- SPOK Hold
- Analyst Count
- IMMP 2
- SPOK 1
- Target Price
- IMMP $8.50
- SPOK $15.00
- AVG Volume (30 Days)
- IMMP 648.0K
- SPOK 180.4K
- Earning Date
- IMMP 05-16-2025
- SPOK 04-30-2025
- Dividend Yield
- IMMP N/A
- SPOK 7.54%
- EPS Growth
- IMMP N/A
- SPOK N/A
- EPS
- IMMP N/A
- SPOK 0.77
- Revenue
- IMMP $3,019,249.00
- SPOK $139,038,000.00
- Revenue This Year
- IMMP $11.25
- SPOK $2.26
- Revenue Next Year
- IMMP $10.22
- SPOK $0.14
- P/E Ratio
- IMMP N/A
- SPOK $21.51
- Revenue Growth
- IMMP 24.11
- SPOK N/A
- 52 Week Low
- IMMP $1.32
- SPOK $13.55
- 52 Week High
- IMMP $3.34
- SPOK $17.96
- Technical
- Relative Strength Index (RSI)
- IMMP 53.43
- SPOK 59.93
- Support Level
- IMMP $1.44
- SPOK $13.55
- Resistance Level
- IMMP $2.71
- SPOK $16.60
- Average True Range (ATR)
- IMMP 0.17
- SPOK 0.61
- MACD
- IMMP 0.05
- SPOK 0.21
- Stochastic Oscillator
- IMMP 29.75
- SPOK 95.22
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.